# Ubrigene

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ubrigene

- Industry: Biotechnology
- Headquarters: Suzhou, China
- Website: www.ubrigene.cn
- Total disclosed funding: $71M
- Latest round: Series C (Apr 19, 2023)
- Investors on record: 19

## About

Established in 2015 and based in Beijing, China, Ubrigene is a biotechnology company that focuses on the development of advanced therapeutic drug technologies. It has GMP production bases in Maryland, Suzhou, Jinan, Guangzhou, Beijing and other places, and CMC global R&D centers in Vancouver and Nanjing. The chairman and CTO of the company, Xiulian Sun graduated from the University of British Columbia and has worked in WZ Biosciences Inc. In 2017, the company's first experimental cell drug entered the clinical stage. In December 2024, it raised approximately CNY 200 million in pre-series D funding.

The company's business includes contract research organization (CRO) and contract development and manufacturing organization (CDMO) services for innovative cell and gene therapy drugs. It focuses on the development and production of clinical-grade viral vectors. Products include DNA (Deoxyribonucleic acid), RNA (Ribonucleic acid), virus, kits, and proteins. Ubrigene also provides analytical testing services. Products can be used to treat cancer, genetic diseases, and ophthalmic diseases.

The company generates revenue by providing CRO, CDMO, and analytical testing services, and therapeutic drugs.

The company will use the pre-series D funding for the construction of commercial production bases of ATMPs CDMO, promoting technology iteration, and improving the service capabilities of CDMO.

## Funding rounds

- Series C, Apr 19, 2023, $22M — GTJA Innovation Investment, Jinan Sci-Tech Venture Capital, FOF Capital, Jinan Jingfa Capital
- Series C, Sep 27, 2022 — CLSA Capital Partners, IDG Capital, Huagai Capital, Ciit Asset Management, Goldstone Capital, Bat Capital, FOF Capital, BGI Co-WIN Investment Management, Wenzhou Investment
- Series B, Sep 16, 2021, $31M — IDG Capital, Cowin Capital, Huagai Capital, Addor Capital, FOF Capital, Ming Bioventures, Zhongguancun Qihang Fund
- Series A, Dec 16, 2020, $18M — Cowin Capital, Huagai Capital, FOF Capital, Ming Bioventures, Zhongguancun Sailing Capital
- Angel, Oct 21, 2019 — Cowin Capital, Chiron Ventures, Tianyou Capital

## Investors

- Cowin Capital (https://capitalatlas.ai/funds/cowin-capital) — Angel, Series A, Series B
- Chiron Ventures — Angel
- Tianyou Capital — Angel
- Huagai Capital (https://capitalatlas.ai/funds/huagai-capital) — Series A, Series B, Series C
- FOF Capital (https://capitalatlas.ai/funds/fof-capital) — Series A, Series B, Series C
- Ming Bioventures (https://capitalatlas.ai/funds/ming-bioventures) — Series A, Series B
- Zhongguancun Sailing Capital — Series A
- IDG Capital (https://capitalatlas.ai/funds/idg-capital) — Series B, Series C
- Addor Capital (https://capitalatlas.ai/funds/addor-capital) — Series B
- Zhongguancun Qihang Fund — Series B
- CLSA Capital Partners (https://capitalatlas.ai/funds/clsa-capital-partners) — Series C
- Ciit Asset Management (https://capitalatlas.ai/funds/ciit-asset-management) — Series C
- Goldstone Capital — Series C
- Bat Capital (https://capitalatlas.ai/funds/bat-capital) — Series C
- BGI Co-WIN Investment Management (https://capitalatlas.ai/funds/bgi-co-win-investment-management) — Series C
- Wenzhou Investment (https://capitalatlas.ai/funds/wenzhou-investment) — Series C
- GTJA Innovation Investment (https://capitalatlas.ai/funds/gtja-innovation-investment) — Series C
- Jinan Sci-Tech Venture Capital (https://capitalatlas.ai/funds/jinan-sci-tech-venture-capital) — Series C
- Jinan Jingfa Capital (https://capitalatlas.ai/funds/jinan-jingfa-capital) — Series C